Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peyrard

Showing results (241-250 of 289) with videos related to

Pageof 29
Sort By:
Plos One|August 10, 2017
Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 studyJohn J Bissler, J Chris Kingswood, Elzbieta Radzikowska, et al.
Epilepsia|October 25, 2021
Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3David N Franz, John A Lawson, Zuhal Yapici, et al.
Haematologica|March 31, 2018
Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia veraMégane Brusson, Maria De Grandis, Sylvie Cochet, et al.
British Journal of Haematology|December 4, 2022
Erythrocyte type 1 equilibrative nucleoside transporter expression in sickle cell disease and sickle cell traitBérengère Koehl, Livia Claude, Karen Reminy, et al.
Transfusion|April 9, 2013
Molecular basis of two novel and related high-prevalence antigens in the Kell blood group system, KUCI and KANT, and their serologic and spatial association with K11 and KETIRandall W Velliquette, Kim Hue-Roye, Christine Lomas-Francis, et al.
Clinical Rheumatology|November 5, 2024
Comparison of group versus individual patient education for promoting safety skills of patients with autoimmune rheumatic diseases treated with biologics: a multicentre randomised controlled trialFrancoise Fayet, Catherine Beauvais, Bruno Pereira, et al.
Clinical and Experimental Immunology|August 8, 2007
Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationshipsN El Houda Agueznay, C Badoual, S Hans, et al.
Plos One|June 24, 2011
Increased expression of the dyslexia candidate gene DCDC2 affects length and signaling of primary cilia in neuronsSatu Massinen, Marie-Estelle Hokkanen, Hans Matsson, et al.
Lancet (London, England)|September 11, 2016
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled studyJacqueline A French, John A Lawson, Zuhal Yapici, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 10, 2015
Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trialJohn J Bissler, John Christopher Kingswood, Elżbieta Radzikowska, et al.
Pageof 29

Showing results (241-250 of 289) with videos related to

Sort By:
Pageof 29
Plos One|August 10, 2017
Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 studyJohn J Bissler, J Chris Kingswood, Elzbieta Radzikowska, et al.
Epilepsia|October 25, 2021
Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3David N Franz, John A Lawson, Zuhal Yapici, et al.
Haematologica|March 31, 2018
Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia veraMégane Brusson, Maria De Grandis, Sylvie Cochet, et al.
British Journal of Haematology|December 4, 2022
Erythrocyte type 1 equilibrative nucleoside transporter expression in sickle cell disease and sickle cell traitBérengère Koehl, Livia Claude, Karen Reminy, et al.
Transfusion|April 9, 2013
Molecular basis of two novel and related high-prevalence antigens in the Kell blood group system, KUCI and KANT, and their serologic and spatial association with K11 and KETIRandall W Velliquette, Kim Hue-Roye, Christine Lomas-Francis, et al.
Clinical Rheumatology|November 5, 2024
Comparison of group versus individual patient education for promoting safety skills of patients with autoimmune rheumatic diseases treated with biologics: a multicentre randomised controlled trialFrancoise Fayet, Catherine Beauvais, Bruno Pereira, et al.
Clinical and Experimental Immunology|August 8, 2007
Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationshipsN El Houda Agueznay, C Badoual, S Hans, et al.
Plos One|June 24, 2011
Increased expression of the dyslexia candidate gene DCDC2 affects length and signaling of primary cilia in neuronsSatu Massinen, Marie-Estelle Hokkanen, Hans Matsson, et al.
Lancet (London, England)|September 11, 2016
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled studyJacqueline A French, John A Lawson, Zuhal Yapici, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 10, 2015
Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trialJohn J Bissler, John Christopher Kingswood, Elżbieta Radzikowska, et al.
Pageof 29